Tris Pharma Reports the Availability of Dyanavel XR (amphetamine) Tablets for Attention Deficit Hyperactivity Disorder
Shots:
- Dyanavel XR has been approved in the US for ADHD in patients aged ≥6yrs. in 2015 & now available as extended-release tablets for oral use
- The results from the P-III study of Dyanavel XR vs PBO in adults with ADHD which were published in the Journal of Clinical Psychiatry showed an improvement in mean PERMP-T scores averaged across all measured post-dose time points
- Additionally, Dyanavel XR extended-release tablets showed an improvement in ADHD symptoms within 1 hr. that persisted through 13 hrs. after QD dosing and were bioequivalent to Dyanavel XR extended-release oral suspension CII while Dyanavel XR improved ADHD symptoms as soon as 30 min. after dosing, based on the separate exploratory study
Ref: PR Newswire | Image: Tris Pharma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
